Board Properly Declared Copaxone Patents Invalid, Federal Circuit Finds
WASHINGTON, D.C. — On the same day it affirmed a Delaware federal judge’s determination of invalidity with regard to four patents covering the multiple sclerosis drug Copaxone, the Federal Circuit U.S....To view the full article, register now.
Already a subscriber? Click here to view full article